



Axxam S.p.A. announces the merger of its two German subsidiaries into Axxam GmbH

January 12, 2022 - Axxam S.p.A. (Milan/Italy), a privately-owned innovative Partner Research Organization (iPRO) announced the merger of its two subsidiaries located in Germany, Hit Discovery Constance GmbH (“HDC”) and IMAX Discovery GmbH (“IMAX”), into Axxam GmbH ^(*), located in Constance (Germany).

Under the new name we will continue to offer our competences, resources and experience to our customers and partners supporting their research projects and facing together the new challenges with a joint and integrated approach.

Axxam GmbH is structured into two business units, namely *Discovery Services Constance* (“DSC”) and *IMAX Discovery*, deriving respectively from the two original companies. Dr. Thilo Enderle will continue in his role as Managing Director of Axxam GmbH and will lead the DSC business unit, while Dr. Marcel Winning will continue to lead the IMAX Discovery business unit.

Offering high-quality services including high-throughput screening (HTS) with plate optical detection (in 1536 and 384 well formats) and complementary technological readouts such as radiometric screening (SPA, flash-plate), *the DSC business unit* will cooperate in unison with the team in Milan responding to the increasing requests from the market for capacity and capabilities in early drug discovery research and specifically in facing challenging HTS projects.

The *IMAX Discovery business unit* will continue offering its clients and partners integrated solutions across the entire discovery process starting from flavor, fragrance and cosmetic target identification and validation up to the selection and development of new bioactive compounds by providing services, tools and integrated solutions tailored to the specific needs of its clients and partners.

The decision to merge our German subsidiaries and to adopt the Axxam brand in Germany is in line with our strategy to strengthen our presence and investments in Germany and to offer to the several clients and partners integrating capacity and capabilities in early discovery research. Furthermore, this will smoothen the intercompany processes increasing efficiency and having access to broader capacity and an integrated set of competences with significant benefits for our clients’ research projects.

^(*) registration still pending

About Axxam S.p.A.

Axxam S.p.A. is a privately owned iPRO (innovative Partner Research Organization) and discovery company with headquarters located at the OpenZone Campus in Bresso (Milan, Italy). The company is a leading provider of discovery services for the entire life sciences industry including pharmaceutical, crop protection, animal health, cosmetics and nutrition. Axxam has a strong expertise across a broad range of discovery disciplines and innovative technologies, including assay development, compound management, HTS and HCS, hit identification and hit validation. Axxam is also engaged in developing novel innovative therapies for diseases with a high unmet medical need.



If you are interested in knowing more about the services offered in the early discovery process for the pharmaceuticals, crop protection and animal health industries, please visit www.axxam.com.

If you are interested in knowing more about the services offered in the food and beverage, flavor and fragrance and cosmetic industries, please visit www.imaxdiscovery.com.